FaithENathanMD
Oncology • Moorestown, NJGenitourinary Oncology, Hematologic Oncology, Thoracic Cancer
Retired
Dr. Nathan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
no office
Moorestown, NJ 08057- Is this information wrong?
Summary
- Dr. Faith Nathan is an oncologist in Moorestown, NJ. She received her medical degree from Rutgers New Jersey Medical School and has been in practice 30 years. She specializes in genitourinary oncology, hematologic oncology, and thoracic cancer and is experienced in immunotherapy, urologic oncology, thoracic oncology, clinical trials as topic, and lung neoplasms. She has more than 40 publications and over 500 citings. She retired in July 2023.
Education & Training
Drexel University College of Medicine/Hahnemann University HospitalFellowship, Hematology and Medical Oncology, 1989 - 1992
Cooper Medical School of Rowan University/Cooper University HospitalResidency, Internal Medicine, 1987 - 1989
Rutgers New Jersey Medical SchoolClass of 1986
Certifications & Licensure
NJ State Medical License 1987 - 2023
PA State Medical License 1988 - 2006- American Board of Internal Medicine Internal Medicine
Clinical Trials
- A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel Start of enrollment: 2006 Mar 01
Publications & Presentations
PubMed
- 24 citationsFirst-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1.Martin Reck, Tudor Ciuleanu, Jong Seok Lee, Michael Schenker, Clarisse Audigier-Valette, B. Zurawski, Helena Linardou, Gregory A. Otterson, Pamela Salman, Makoto Nishi...> ;Journal of Thoracic Oncology. 2021 Apr 1
- 1507 citationsNivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.Matthew D. Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, B. Zurawski, Sang-We Kim, Enric Carcereny Costa, Keunchil Park, A. Alexandru, L. Lupinacci, Emmanuel de la Mora...> ;The New England Journal of Medicine. 2019 Sep 28
- 136 citationsNivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outco...Martin Reck, Michael Schenker, Ki Hyeong Lee, Mariano Provencio, Makoto Nishio, Krzysztof Lesniewski-Kmak, Randeep Sangha, Samreen Ahmed, Judith Raimbourg, Kynan Feene...> ;European Journal of Cancer. 2019 Jun 11
- Join now to see all
Journal Articles
- Pain in castration-resistant prostate cancer with bone metastases: a qualitative studyGater A, Abetz-Webb L, Battersby C, Parasuraman B, McIntosh S, Nathan F, Piault EC, Health & Quality of Life Outcomes, 2011
- Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care populationEngel-Nitz NM, Alemayehu B, Parry D, Nathan F, Cancer management and research, 2011
- A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advan...Chouaid C, Nathan F, Pemberton K, Morris T, Cancer Chemother Pharmacol, 2011
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
